CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based therapeutics targeting rare inherited diseases involving the liver and for cancers that are genetically defined, announced that the Company will release its third quarter 2015 financial results after market close on Tuesday, November 10, 2015.
Help employers find you! Check out all the jobs and post your resume.
